EDG-7500

Boulder, Colorado, U.S., September 22, 2026 Edgewise Therapeutics, Inc. has unveiled new preclinical pharmacology findings describing the differentiated mechanism...

BOULDER, Colo., May 7, 2026 Edgewise Therapeutics reported first quarter 2026 financial results while highlighting major progress across its...

BOULDER, Colorado | December 24, 2025 — Edgewise Therapeutics announced the completion of Parts B and C of the...